COVID-19, IP and access: Will the current system of medical innovation and access to medicines meet global expectations?

@article{Gurgula2021COVID19IA,
  title={COVID-19, IP and access: Will the current system of medical innovation and access to medicines meet global expectations?},
  author={O. Gurgula and W. H. Lee},
  journal={Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector},
  year={2021},
  volume={17},
  pages={61 - 70}
}
  • O. Gurgula, W. H. Lee
  • Published 2021
  • Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector
The COVID-19 pandemic has exposed the fundamental flaws in the current system of medical innovation and access to medicines, which require urgent attention from the global community. This is prompted by the experience of the past decades, which has proven that this system was ineffective in securing adequate access to medicines for all. The understanding of the deficiencies of the existing system is crucial today, as it may help to design effective approaches for improving access. This article… Expand

References

SHOWING 1-10 OF 84 REFERENCES
Strategic Patenting by Pharmaceutical Companies – Should Competition Law Intervene?
  • O. Gurgula
  • Medicine, Business
  • IIC; international review of industrial property and copyright law
  • 2020
Should All Drugs Be Patentable?: A Comparative Perspective
Comment: Compulsory Licensing of Patented Pharmaceutical Inventions: Evaluating the Options
  • J. Reichman
  • Business, Medicine
  • The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics
  • 2009
The productivity crisis in pharmaceutical R&D
Diagnosing the decline in pharmaceutical R&D efficiency
...
1
2
3
4
5
...